Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Pioneering strategy to deliver localised chemotherapy for liver cancer

Reference number
Coordinator DOUBLE BOND PHARMACEUTICALS AB - Double Bond Pharmaceutical AB
Funding from Vinnova SEK 500 000
Project duration April 2017 - October 2017
Status Completed

Purpose and goal

The aim of the project was to analyze and evaluate the clinical and market feasibility of SA-033, our innovative drug against liver cancer. During the project, we have also defined all details related to the planned phase 1 clinical validation. The set goals were satisfactorily fulfilled.

Expected results and effects

In the project, we have confirmed the clinical and market feasibility of SA-033 as well as defined all details related to the planned phase 1 clinical validation. The results of our analyzes and assessments will provide a basis for our strategic decisions related to the development of the drug.

Planned approach and implementation

During the course of the project, we have performed an advanced market analysis including, for instance, the competitive landscape, user needs and regulatory aspects. We have also identified potential partners for the planned out-licensing deal and defined the company´s financial expectations connected to it. In addition, we have developed a plan for the following phase I clinical validation that will be a significant step towards commercialization of the drug.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 January 2019

Reference number 2017-02436

Page statistics